New study checks if HIV subtype affects success of monthly shots
NCT ID NCT07370649
First seen Feb 01, 2026 · Last updated May 16, 2026 · Updated 13 times
Summary
This study looks at how well a long-acting injectable HIV treatment (cabotegravir and rilpivirine) works in people with HIV-1 subtype A6, a common strain in Eastern Europe. Researchers will compare their outcomes to those with other subtypes using medical records from 250 adults in Poland, Germany, and the Czech Republic. The goal is to see if knowing a patient's HIV subtype helps doctors choose the best treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Katedra Chorób Zakaźnych i Niedoborów Immunologicznych
Szczecin, West Pomeranian Voivodeship, 71-455, Poland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.